MEA UTI Drugs Market Share

Middle East and Africa Urinary Tract Infection (UTI) Drugs Market Overview

The Mea Uti Drugs Market Size was valued at USD 1.55 Billion in 2023. The Global Mea Uti Drugs industry is projected to grow from USD 1.63 Billion in 2024 to USD 2.39 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.98% during the forecast period (2024 - 2032).

Urinary tract infection (UTI) is the infection of the lower or upper urinary tract generally due to escherichia coli although other bacteria and fundi may be causative organisms. Symptoms include pain with  urination, frequent urination and feeling the need to urinate despite having an empty bladder. Risk factors that may cause UTI include female anatomy, sexual intercourse, diabetes, obesityetc. World Health Organization (WHO) estimates that approximately 50 % of women suffer from UTI at some point of time in their lives resulting in more than 1 million hospitalizations per year. WHO estimates the annual cost of UTI infections treatment to be greater than $1 billion. It has further been stated that 1% of boys and 3-8% of girls are diagnosed with UTI. .

The Middle East and African urinary tract infection (UTI) drugs market is growing due to factors such as catheter associated UTI, hospital borne infections (nosocomial infections), child birth, old age, obesity, growing health awareness especially about women health etc. However, there remain market constraints such as drug resistance, unmet clinical needs, increasing incidence of chronic diseases etc. Another prominent restrain is the excellent efficacy of present antibiotics specially the quinolones. However the rise of drug resistance has negated this constraint and had opened doors to new drug development as a good strategy for UTI treatment.

One of the most common health problems is a urinary tract infection (UTI). Women experience health issues like menopause, pregnancy, and some side effects of contraception that make UTI more likely in them than in males. However, the market for treating urinary tract infections faces global difficulties since people are reluctant to seek the proper diagnosis from medical professionals. However, there are still market restrictions, including medication resistance, unmet clinical demands, and the prevalence of chronic illness. The remarkable efficacy of current antibiotics, particularly quinolones, is a significant barrier. However, the rise in antibiotic resistance has eliminated this restriction and made it possible to develop new drugs as an effective method of treating UTIs.

The prevalence of multidrug-resistant gram-negative bacteria in patients hospitalized with complex urinary tract infections (cUTI) is predicted by ongoing study and development efforts in the market for treating urinary tract infections. Stakeholders are using the mixed-effects logistic regression framework to examine patient symptoms. Both advanced and developing nations' aging populations will help the market. As the number of seniors increases quickly, it is anticipated that age-related ailments, including diabetes, kidney and liver disease, and others, will become increasingly prevalent. The detection and management of such disorders have led to increased prescriptions for tests like creatinine, glucose, ketones, albumin, and bilirubin. This market is anticipated to grow because urinalysis is utilized to conduct these tests.

The high prevalence of diseases, sizable patient population, medical tourism growth, healthcare system development, and increased earnings in these countries. Many players are turning their attention to emerging regions as the markets in the Middle East and Africa regions mature. Big investments in medical and biological research must be made in emerging regions if laboratory infrastructure is to be improved. Due to the growth of the urinalysis market, diagnostic equipment is increasingly being installed in laboratories. The affordability of refurbished equipment threatens the sector's expansion, which serves the same purposes as fresh instruments but is less expensive. The economy may use more secondhand items due to weak regulatory systems.

Study Objectives Middle East and Africa Urinary Tract Infection (UTI) Drugs Market:

• To provide detail analysis of the market structure along with forecast for the next 5 years about various segments and sub segments of the Middle East and African UTI Drugs market.


• To provide insights about factors affecting the market growth.


• To analyze the market based on various analyses which includes price analysis, supply chain analysis, Porters Five Force analysis etc.


• To provide past and estimated future revenue of Middle East and Africa UTI drugs market’s segments and sub-segments.


• To provide country level analysis of the market with respect to the current market size and future growth prospect.


• To provide country level analysis of the market’s segments which includes by drug class, by clinical indication, by end users and other sub segments.


• To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies and drawing a competitive landscape of the market


• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments taking place globally.

Intended Audience

• UTI drugs manufacturers


• UTI drugs suppliers


• Private research laboratories


• Research and development (R&D) companies


• Market research and consulting service providers


• Government research laboratories


• Contract manufacturing organizations

Key Players of Middle East and Africa UTI Drugs Market

Some of the key players in Middle East and Africa Urinary Tract Infection (UTI) Drugs Market are: 

• Bayer AG


• Novartis AG


• Pfizer Inc.


• F. Hoffmann-La Roche Ltd


• AstraZeneca 


• Cipla Inc.


• Dr. Reddy’s Laboratories Ltd. 

Middle East and Africa UTI Drugs Market Segmentation

Middle East and Africa Urinary Tract Infection (UTI) Drugs Market has been segmented on the basis of drug class which comprises of quinolones, aminoglycosides, β-lactam, azoles and others. On the basis of clinical indications Middle East and Africa Urinary Tract Infection (UTI) Drugs Market is segmented into urethritis, cystitis, and pyelonephritis. On the basis of end users the Middle East and Africa Urinary Tract Infection (UTI) Drugs Market is segmented into hospitals and self-administered.

News:

Perhaps sooner than anticipated, a new class of antibiotics for treating UTIs will be accessible. The pharmaceutical company GSK's gepotidacin is being hailed as "novel" or "first-in-class" because it inhibits or delays bacterial DNA replication. Gepotidacin, should it be authorized, would become the first novel antibiotic created for treating UTIs in over twenty years. Additionally, it would be accessible no later than twelve months before the anticipated study's conclusion. As a result of the early testing's success, the Independent Data Monitoring Committee has recommended moving on to the following stage.

Regional Analysis of Middle East and Africa UTI Drugs Market

UAE is the largest market of UTI drugs Middle East and Africa Urinary Tract Infection (UTI) Drugs Market closely followed by Egypt. South Africa ranks high in the agendas of many Indian based pharmaceutical firms. The rest of African market is the fastest growing Middle East and Africa Urinary Tract Infection (UTI) Drugs Market since there are huge unmet medical needs.

The report about Middle East and Africa Urinary Tract Infection (UTI) Drugs Market by Market Research Future comprises extensive primary research along with detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. 

The report gives a clear picture of current market scenario which includes past and estimated future Middle East and Africa Urinary Tract Infection (UTI) Drugs Market size with respect to value & volume, technological advancement, macro economical and governing factors in the Middle East and Africa Urinary Tract Infection (UTI) Drugs Market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of different markets segments and regions.